www.amphionplc.com
Amphion builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.
Amphion has a significant shareholding in 8 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.
Amphion investee Myconostica wins diagnostics innovation award from UK Northwest biotech support body
Amphion Innovations PLC (AIM: AMP) investee company Myconostica Ltd said it has won this year’s award for ‘Innovation in Diagnostics Project of the Year’ from BioNoW, the cluster support group for the Northwest of England's biotechnology, pharmaceutical and healthcare industry.
The award was received for Myconostica’s MycArray Yeast ID product; a= system for identifying Candida yeast species.
Myconostica, in which Amphion holds a 22 percent stake, is a UK-based medical diagnostic company specialised in molecular diagnostic tests for life-threatening fungal infections.
MycArray Yeast ID utilises microarray technology to identify 18 different yeast species from yeast positive blood cultures. Several Candida species are well-documented as exhibiting resistance or a decreased susceptibility to certain anti-fungal drugs commonly used in the treatment of invasive yeast infections. Rapid and accurate identification of Candida species in patients suffering from candidemia is imperative for clinicians thus enabling correct anti-fungal therapies to be administered.
Studies have shown that the administration of targeted therapies in patients with candidemia significantly improve patient outcomes. In excess of 100,000 people globally are believed to suffer from invasive infections caused by Candida species each year, Mycoconostica said.
Chief operating officer John Thornback said “Having been the recipients of BioNoW’s Biomedical Start Up of the Year Award in 2006 we are delighted to have been further recognised for our continued contribution to providing innovative diagnostic solutions for the treatment of invasive fungal diseases”.
The Northwest Biomedical Awards are held annually by BioNoW to formally recognise the excellence and efforts of Northwest companies within the biomedical sector.
Amphion’s other investments include a 19.99 percent stake in Kromek, 15.3 percent in Firestar Software, 8.5 percent in Axcess International, 38.5 percent in Motif Biosciences, 50 percent in MSA Holdings B.S.C., 24.4 percent in M2M Imaging Corp, 25 percent in Private Markets, 14.6 percent in WellGen and 100 percent in DataTern.
Amphion builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.
It does not invest in speculative technologies requiring long development timeframes or excessive capital investment; it looks for defensible core intellectual property and know-how for long-term competitive advantage, and growth potential in very large markets of at least US$1 billion in size. Each partner company is chosen with the goal of achieving an exit valuation in excess of US$100 million.
